Pricing New Drugs for COVID-19 in the Pharmaceutical Industry: Insights From the Chinese Medical Insurance
International Journal of Health Policy and Management · 2023
DOI: 10.34172/ijhpm.2023.7972 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Health Policy and Management, 2023. Verfasst von Jinmiao Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Insurance. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Pharmacy, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
- NHC Key Laboratory of Health Technology Assessment, Department of Health Economics, School of Public Health, Fudan University, Shanghai, China.
ORCID-Profile: Jinmiao Lu, Xiaohua Ying, Zhiping Li
Zitieren
APA
Lu, J., Ying, X., & Li, Z. (2023). Pricing New Drugs for COVID-19 in the Pharmaceutical Industry: Insights From the Chinese Medical Insurance. International Journal of Health Policy and Management. https://doi.org/10.34172/ijhpm.2023.7972
Vancouver
Lu J, Ying X, Li Z. Pricing New Drugs for COVID-19 in the Pharmaceutical Industry: Insights From the Chinese Medical Insurance. International Journal of Health Policy and Management. 2023. doi:10.34172/ijhpm.2023.7972
BibTeX
@article{Lu2023,
author = {Lu, Jinmiao and Ying, Xiaohua and Li, Zhiping},
title = {Pricing New Drugs for COVID-19 in the Pharmaceutical Industry: Insights From the Chinese Medical Insurance},
journal = {International Journal of Health Policy and Management},
year = {2023},
doi = {10.34172/ijhpm.2023.7972}
}
EUVIMED